Literature DB >> 2165251

Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates.

R G Shea1, J C Marsters, N Bischofberger.   

Abstract

Triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (2) was coupled to the 5' terminus of oligodeoxynucleotides via hydrogen phosphonate solid support DNA synthesis methodology. Duplex DNA oligomers with a single 5'-phospholipid melted at lower temperatures than the corresponding unmodified duplex, but duplexes bearing lipids at each 5' end had higher Tms. In uptake experiments with L929 cells, 8-10 times more lipid-DNA became cell-associated than did unmodified DNA. Unmodified antisense diesters were inactive in a VSV antiviral assay in L929 cells (at up to 200 microM). Attachment of a lipid to the oligomer, however, led to a greater than 90% at 150 microM (greater than 80% at 100 microM) reduction in viral protein synthesis. The antiviral activity depended on the sequence of the oligodeoxynucleotide, but some compounds having little or no base complementarity to the viral target were also effective. Phosphorothioate derivatives reduced viral protein synthesis by 20-30% at 100 microM in the VSV assay. The lipid-DNA compounds were not toxic to the cells at up to 100 microM.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165251      PMCID: PMC331077          DOI: 10.1093/nar/18.13.3777

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  47 in total

Review 1.  Antisense compounds: potential role in cancer therapy.

Authors:  C A Stein; J S Cohen
Journal:  Important Adv Oncol       Date:  1989

2.  Characterization of a lipophilic prodrug of 5-fluorouracil with a cholesterol promoiety and its application to liposomes.

Authors:  M Hashida; K Sato; Y Takakura; H Sezaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-08       Impact factor: 1.645

3.  DNA-protein conjugates can enter mitochondria via the protein import pathway.

Authors:  D Vestweber; G Schatz
Journal:  Nature       Date:  1989-03-09       Impact factor: 49.962

4.  Virus plaque-reduction assay for interferon: microplaque and regular macroplaque reduction assays.

Authors:  M P Langford; D A Weigent; G J Stanton; S Baron
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Chemical and enzymatic biotin-labeling of oligodeoxyribonucleotides.

Authors:  T Kempe; W I Sundquist; F Chow; S L Hu
Journal:  Nucleic Acids Res       Date:  1985-01-11       Impact factor: 16.971

7.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Authors:  P C Zamecnik; J Goodchild; Y Taguchi; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.

Authors:  T Matsushita; E K Ryu; C I Hong; M MacCoss
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

9.  Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety.

Authors:  J G Turcotte; S P Srivastava; J M Steim; P Calabresi; L M Tibbetts; M Y Chu
Journal:  Biochim Biophys Acta       Date:  1980-09-08

10.  Synthesis of DNA via deoxynucleoside H-phosphonate intermediates.

Authors:  B C Froehler; P G Ng; M D Matteucci
Journal:  Nucleic Acids Res       Date:  1986-07-11       Impact factor: 16.971

View more
  21 in total

1.  Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups.

Authors:  C MacKellar; D Graham; D W Will; S Burgess; T Brown
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

Review 2.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

3.  Site-specific introduction of functional groups into phosphodiester oligodeoxynucleotides and their thermal stability and nuclease-resistance properties.

Authors:  Y Nomura; Y Ueno; A Matsuda
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

4.  Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.

Authors:  V Prasad; S Hashim; A Mukhopadhyay; S K Basu; R P Roy
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 5.  Inhibition of gene expression by anti-sense oligodeoxynucleotides.

Authors:  R Q Zheng; D M Kemeny
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

6.  Synthesis and hybridization properties of oligonucleotides containing 2'-O-modified ribonucleotides.

Authors:  T H Keller; R Häner
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

Review 7.  Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids.

Authors:  Arnaud Gissot; Michel Camplo; Mark W Grinstaff; Philippe Barthélémy
Journal:  Org Biomol Chem       Date:  2008-03-05       Impact factor: 3.876

Review 8.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

9.  Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates.

Authors:  E Bonfils; C Depierreux; P Midoux; N T Thuong; M Monsigny; A C Roche
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

Review 10.  Reactive oligonucleotide derivatives as gene-targeted biologically active compounds and affinity probes.

Authors:  D G Knorre; V V Vlassov
Journal:  Genetica       Date:  1991       Impact factor: 1.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.